Immatics N.V. Ordinary Shares IMTX
$6.82
-0.22%
at last close
Market Cap$1.04 billion
P/E Ratio—
Div Yield—
Volume995.5K
52-Week Range
$5.67$12.41
Analyst Ratings
- Consensus
- Buy — 6 Buy · 0 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $20.00 (+193.5% upside)
Key Stats
- Today's Range
- $6.73 – $7.20
- 50-Day Range
- $6.73 – $9.98
- 52-Week Range
- $5.67 – $12.41
- Volume
- 996K shs
- Average Volume
- 790K shs
- Market Cap
- $1.04 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.01%
- Days to Cover
- 1.00
About Immatics N.V. Ordinary Shares
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Related Stocks
Compare head-to-head: IMTX vs NVDA·IMTX vs AAPL·IMTX vs GOOGL·IMTX vs GOOG
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.